表紙
市場調查報告書

醫療用大麻:專題研究

Medical Marijuana - Thematic Research

出版商 GlobalData 商品編碼 918530
出版日期 內容資訊 英文 186 Pages
訂單完成後即時交付
價格
醫療用大麻:專題研究 Medical Marijuana - Thematic Research
出版日期: 2019年11月30日內容資訊: 英文 186 Pages
簡介

全球主要國家 - 美國、歐洲 (法國、德國、義大利、西班牙、英國)、加拿大、以色列、澳洲 - 醫療用大麻市場規模已於2018年達5000萬美元以上。預估未來將以81.3%的CAGR (複合年均增長率) 於2025年成長至32億美元規模。

本報告研究全球醫療用大麻市場,彙整產品概要及SWOT分析、整體產業臨床進展情況、具前景的已上市/PIPELINE產品、近期交易情況、醫師和患者的期待與擔憂、未來市場成長預測值等情報。

第1章 前言

第2章 摘要整理

第3章 醫療用大麻:概要

  • 醫療用大麻定義
  • 大麻素概要
  • 大麻素受體概要
  • 內源性大麻素系統

第4章 醫療用大麻:全球市場概況

  • 醫療用大麻歷史
  • 美國醫療用大麻市場
  • 法國醫療用大麻市場
  • 德國醫療用大麻市場
  • 義大利醫療用大麻市場
  • 西班牙醫療用大麻市場
  • 英國醫療用大麻市場
  • 加拿大醫療用大麻市場
  • 以色列醫療用大麻市場
  • 澳洲醫療用大麻市場
  • 媒體中的醫療用大麻

第5章 已上市產品

  • 已上市產品:按症狀
  • 已上市產品簡介
  • 投藥途徑
  • 已上市產品SWOT分析

第6章 PIPELINE產品評估

  • 臨床後期階段PIPELINE產品概要
  • 臨床後期階段PIPELINE產品:按症狀
  • Phase II的PIPELINE產品
  • Phase III的PIPELINE產品
  • PIPELINE產品SWOT分析

第7章 臨床試驗

  • 臨床階段大麻產品:概要
  • 進行中的臨床試驗
  • 早期階段創新方法
  • 大型臨床贊助商

第8章 研發策略

  • 取得臨床試驗施行許可
  • 臨床試驗後期階段企業
  • 臨床試驗設計
  • 產品PIPELINE:按投藥途徑 (RoA)

第9章 臨床試驗早期階段PIPELINE產品

  • 主要針對症狀:早期階段PIPELINE產品的情況

第10章 醫療用大麻主要針對症狀:神經性厭食症

  • 神經性厭食症:概要
  • 厭食症的併發症
  • 治療策略
  • 厭食症的內生性大麻系統
  • 厭食症醫療用大麻產品

第11章 醫療用大麻主要針對症狀:肌肉痙攣

  • 肌肉痙攣:概要
  • 肌肉類型
  • 肌肉收縮
  • 肌肉痙攣病因
  • 肌肉痙攣治療演算法
  • 肌肉痙攣醫療用大麻產品

第12章 醫療用大麻主要針對症狀:疼痛

  • 疼痛:概要
  • 疼痛類型
  • 神經性疼痛
  • 癌症疼痛
  • 疼痛醫療用大麻產品

第13章 醫療用大麻主要針對症狀:癲癇

  • 癲癇:概要
  • 癲癇病理生理學
  • 癲癇類型
  • 兒童發作癲癇
  • 癲癇醫療用大麻產品

第14章 案例研究:Charlotte's Web

  • Charlotte Figi治療案例
  • KOL (專家) 觀點

第15章 產業分析

  • 利害相關人考察

第16章 交易環境

  • 策略性市場重整
  • 企業併購

第17章 價格和醫藥費償付策略

  • 價格和醫藥費償付:美國
  • 歐盟和法國的價格和醫藥費償付
  • 德國國內藥價
  • 義大利國內藥價
  • 西班牙/英國/澳洲國內藥價
  • 加拿大/以色列國內藥價
  • KOL (專家) 觀點

第18章 未滿足需求

  • 未滿足需求概要
  • KOL (專家) 觀點

第19章 市場課題和機會

  • 醫療用大麻藥物治療挑戰
  • 醫療用大麻藥物治療市場機會

第20章 處方者 (醫師) 觀點

  • 整體趨勢和建議
  • 按國家的趨勢:美國、歐洲主要5國 (EU5)、加拿大、以色列、澳洲

第21章 消費者觀點

  • 整體趨勢和建議
  • 按國家的趨勢:美國、歐洲主要5國 (EU5)、加拿大、以色列、澳洲

第22章 市場展望

  • 醫療用大麻的未來
  • 市場推動因素
  • 市場阻礙因素
  • 市場潛力
  • 主要分析結果
  • 結論:KOL (專家) 觀點

第23章 附錄

目錄
Product Code: GDHCHT042

Marketed and approved medical marijuana products generated sales of at least $50m across the US, the 5EU (France, Germany, Italy, Spain and the UK), Canada, Israel and Australia in 2018. The actual value of this market is expected to be far greater, growing at a compound annual growth rate (CAGR) of 81.3% to reach $3.2bn by 2025. There are 11 medical marijuana products in late-stage clinical trials. Drug candidates Zygel (cannabidiol) and lenabasum are being developed by US biopharmaceutical companies Zynerba Pharma and Corbus Pharma, respectively, and are expected to launch in the US and 5EU markets in 2021.

Both Zygel and lenabasum were granted fast track and orphan drug designation by the US Food and Drug Administration (FDA), and are expected to generate sales of $417m and $771m in 2025, respectively. Contributing to the high sales figures for these late-stage pipeline agents is the fact that Zygel and lenabasum are both being developed to treat multiple disorders from a variety of therapy areas, including genetic disorders, musculoskeletal conditions and autoimmune diseases.

A lot of these patients are children that have a poor quality of life, so the need for effective medicines is urgent. Products entering the market are likely to be well received, especially if there are no psychological side effects, which is a common concern of prescribing physicians and patients alike. Many of the medical marijuana products in development contain non-psychoactive compounds; a research and development (R&D) strategy designed to position drug candidates favorably when companies apply for marketing authorization from bodies such as the FDA and the European Medicines Agency (EMA).

Aside from the promising prospects for late-stage drug candidates, marketed therapies such as GW Pharma's Epidiolex (cannabidiol) will significantly drive market growth. The impact of Epidiolex has been immense. The drug, which generated sales of $4.7m in 2018, is expected to reach annual sales of $1.9bn by 2025.

However, unmet needs such as the expensive cost of therapy, the lack of data to support the use of medical marijuana and confusing or non-existent treatment guidelines leave some doctors reluctant to prescribe these products. These factors among others will continue to be obstacles in the medical marijuana marketplace throughout the foreseeable future.

The latest report "Medical Marijuana- Thematic Research" combines key opinion leader insight, interviews with industry experts and surveys of prescribing physicians and consumers in the US, France, Germany, Italy, Spain, the UK, Canada, Israel and Australia to provide an in-depth review of the medical marijuana market.

The report includes an assessment of ongoing clinical trials, the geographical location of trial sponsors, discussion of the key players in the medical marijuana space as well as insights from industry experts discussing market challenges and considerations of stakeholders in the arena.

Key Questions Answered in This Report

  • What was the value of the medical marijuana market in 2018?
  • What challenges do biopharmaceutical companies developing medical marijuana therapeutics face that are unique to this field?
  • Which patients do prescribing physicians think are most likely to benefit from treatment with medical marijuana?
  • What are the concerns and perceptions of prescribers and potential consumers of medical marijuana across the nine markets covered in this report?
  • What are the unmet needs in the medical marijuana market and what opportunities remain for industry players?

Scope

  • Overview of the potential applications of medical marijuana including SWOT analysis of marketed and late-stage pipeline agents
  • In-depth analysis of diseases where at least one medical marijuana product is used in clinical practice
  • Key topics covered include assessment of strategic consolidations, unmet needs, clinical trial mapping, examination of market opportunities and challenges
  • Discussion of late-stage pipeline products including a sales forecast from 2018-2025
  • Pipeline analysis: comprehensive data and discussion of emerging trends, the significance of the endocannabinoid system in various conditions, the route of administration of pipeline agents and the markets in which the drugs are expected to launch.
  • Analysis of the current and future market competition in the global medical marijuana therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global medical marijuana market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global medical marijuana market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Preface

  • 1.1 Table of Contents
  • 1.2 Abbreviations
  • 1.3 Related Reports

2. Executive Summary

  • 2.1 Key Findings
  • 2.2 KOL Insights

3. Introduction to Medical Marijuana

  • 3.1 Defining Medical Marijuana
  • 3.2 Overview of Cannabinoids
  • 3.3 Overview of Cannabinoid Receptors
  • 3.4 The Endocannabinoid System

4. Medical Marijuana: The Global Picture

  • 4.1 The History of Medical Marijuana
  • 4.2 Medical Marijuana in the US
  • 4.3 Medical Marijuana in France
  • 4.4 Medical Marijuana in Germany
  • 4.5 Medical Marijuana in Italy
  • 4.6 Medical Marijuana in Spain
  • 4.7 Medical Marijuana in the UK
  • 4.8 Medical Marijuana in Canada
  • 4.9 Medical Marijuana in Israel
  • 4.10 Medical Marijuana in Australia
  • 4.11 Medical Marijuana in the Media

5. Marketed Products

  • 5.1 Marketed Products by Indication
  • 5.2 Marketed Product Profiles
  • 5.3 Dosing
  • 5.4 SWOT Analysis of Marketed Products

6. Pipeline Assessment

  • 6.1 Overview of Late-Stage Pipeline Products
  • 6.2 Late-Stage Pipeline Products by Indication
  • 6.3 Phase II Pipeline Products
  • 6.4 Phase III Pipeline Products
  • 6.5 SWOT Analysis of Pipeline Products

7. Clinical Trials

  • 7.1 Overview of Marijuana Products in Clinical Development
  • 7.2 Ongoing Clinical Trials
  • 7.3 Innovative Early-Stage Approaches
  • 7.4 Leading Industry Sponsors

8. R&D Strategies

  • 8.1 Receiving Permission to Conduct Clinical Trials
  • 8.2 Companies in the Late-Stage Pipeline
  • 8.3 Clinical Trial Design
  • 8.4 Pipeline by Route of Administration

9. Early-Stage Pipeline Products

  • 9.1 Indications in the Early-Stage Pipeline

10. Focus Indication: Anorexia Nervosa

  • 10.1 Introduction to Anorexia Nervosa
  • 10.2 Complications of Anorexia
  • 10.3 Treatment Strategies
  • 10.4 The Endocannabinoid System in Anorexia
  • 10.5 Medical Marijuana Products for Anorexia

11. Focus Indication: Muscle Spasticity

  • 11.1 Introduction to Muscle Spasticity
  • 11.2 Muscle Types
  • 11.3 Muscle Contraction
  • 11.4 Etiology of Muscle Spasticity
  • 11.5 Treatment Algorithm for Muscle Spasticity
  • 11.6 Medical Marijuana Products for Muscle Spasticity

12. Focus Indication: Pain

  • 12.1 Introduction to Pain
  • 12.2 Types of Pain
  • 12.3 Neuropathic Pain
  • 12.4 Cancer Pain
  • 12.5 Medical Marijuana Products for Pain

13. Focus Indication: Epilepsy

  • 13.1 Introduction to Epilepsy
  • 13.2 The Pathophysiology of Seizures
  • 13.3 Types of Seizures
  • 13.4 Childhood-Onset Epilepsies
  • 13.5 Medical Marijuana Products for Epilepsy

14. Case Study: Charlotte's Web

  • 14.1 The Story of Charlotte Figi
  • 14.2 KOL Perspectives

15. Industry Insights

  • 15.1 Considerations of Stakeholders

16. Deals Landscape

  • 16.1 Strategic Consolidations
  • 16.2 Mergers and Acquisitions

17. Pricing and Reimbursement Strategy

  • 17.1 Pricing and Reimbursement in the US
  • 17.2 Pricing and Reimbursement in the EU and France
  • 17.3 Drug Prices in Germany
  • 17.4 Drug Prices in Italy
  • 17.5 Pricing in Spain, the UK and Australia
  • 17.6 Pricing in Canada and Israel
  • 17.7 KOL Perspectives

18. Unmet Needs

  • 18.1 Overview of Unmet Needs
  • 18.2 KOL Perspectives

19. Market Challenges and Opportunities

  • 19.1 Challenges for Medical Marijuana Pharmacotherapy
  • 19.2 Opportunities for Medical Marijuana Pharmacotherapy

20. Prescriber Perspectives

  • 20.1 Take-Home Messages from the Prescriber Survey
  • 20.2 Key Messages from US Prescribers
  • 20.3 Key Messages from 5EU Prescribers
  • 20.4 Key Messages from Canadian Prescribers
  • 20.5 Key Messages from Israeli Prescribers
  • 20.6 Key Messages from Australian Prescribers

21. Consumer Perspectives

  • 21.1 Take-Home Messages from the Consumer Survey
  • 21.2 Consumer Perspectives in North America
  • 21.3 Consumer Perspectives in the 5EU
  • 21.4 Consumer Perspectives in Israel
  • 21.5 Consumer Perspectives in Australia

22. Market Outlook

  • 22.1 The Future of Medical Marijuana
  • 22.2 Market Drivers
  • 22.3 Market Barriers
  • 22.4 Market Potential
  • 22.5 Take-Home Messages
  • 22.6 Closing Statements from Industry Experts and KOLs

23. Appendix

  • 23.1 Sources
  • 23.2 Study Design
  • 23.3 Methodology
  • 23.4 Primary Research
  • 23.5 About the Authors
  • 23.6 About GlobalData
  • 23.7 Contact Us